RecruitingPhase 2NCT06476132

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Studying Bronchiolitis obliterans

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Scott M. Palmer, M.D., M.H.S.
Duke University Medical Center: Transplantation
Intervention
Belumosudil(drug)
Enrollment
234 enrolled
Eligibility
12 years · All sexes
Timeline
20252027

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06476132 on ClinicalTrials.gov

Other trials for Bronchiolitis obliterans

Additional recruiting or active studies for the same condition.

See all trials for Bronchiolitis obliterans

← Back to all trials